姑息性放疗能否影响接受全身治疗（化疗或阿比特龙）的去势抵抗性前列腺癌患者的前列腺特异性抗原反应？——三例报告

Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?-a report of three cases.

作者信息

Hingorani Mohan, Dixit Sanjay, Pugazhenthi Pattu, Hawkyard Simon, Robertson Andrew, Khafagy Richard

机构信息

1 Department of Clinical Oncology, Castle Hill Hospital, Hull and East Yorkshire, NHS Trust, Cottingham, East Riding of Yorkshire, HU16 5JQ, UK ; 2 Department of Urology, Scarborough District General Hospital, Scarborough ON M1P 2V5, UK.

出版信息

Cancer Biol Med. 2015 Mar;12(1):60-3. doi: 10.7497/j.issn.2095-3941.2014.0025.

DOI:10.7497/j.issn.2095-3941.2014.0025

PMID:25859413

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4383847/

Abstract

Palliative radiotherapy (pRT) is primarily employed for palliation of bone pain in patients with castrate-resistant prostate cancer (CRPC). However, evidence that pRT influences prostate-specific antigen response in patients with CRPC on systemic therapy is lacking. We describe three cases of CRPC progressing after treatment with docetaxel (n=2) and abiraterone (n=1), who responded unusually after pRT for bone pain with the development of a significant biochemical response and restoration of response to systemic therapy. The possibility of pRT influencing metastatic disease in CRPC has not been previously reported, and raises the possibility of radiation-induced modulation of anti-tumor immune response mechanisms that may play a role in the restoration of response to systemic treatment.

摘要

姑息性放疗（pRT）主要用于缓解去势抵抗性前列腺癌（CRPC）患者的骨痛。然而，缺乏证据表明pRT会影响接受全身治疗的CRPC患者的前列腺特异性抗原反应。我们描述了3例CRPC患者，其中2例在接受多西他赛治疗、1例在接受阿比特龙治疗后病情进展，他们在接受pRT治疗骨痛后出现了异常反应，出现了显著的生化反应并恢复了对全身治疗的反应。此前尚未报道pRT影响CRPC转移疾病的可能性，这增加了辐射诱导抗肿瘤免疫反应机制调节的可能性，而这可能在恢复对全身治疗的反应中发挥作用。